Results 151 to 160 of about 181,641 (286)
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
, 2011 Major interest surrounds how angiotensin II triggers cardiac hypertrophy via epidermal growth factor receptor transactivation. G protein-mediated transduction, angiotensin type 1 receptor phosphorylation at tyrosine 319, and β-arrestin-dependent ...
Pearson, Richard B. +19 more
core +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera +12 more
wiley +1 more source
Angiotensin type 2 receptor expression in kidney during angiotensin type 1 receptor blockade [PDF]
American Journal of Hypertension, 2002 openaire +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source